AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 252 min read$WT

Should You Buy WisdomTree (WT) Stock After Its Latest Crypto Move?

WisdomTree (WT) reported record AUM of $162.9B in Q2 2026, up 30% YoY, with revenue at $177.2M and 40.5% operating margin. The company partnered with MoonPay to integrate its tokenized fund WTGXX, accessing 35M accounts. Despite GAAP losses from debt repurchases, management highlights long-term growth potential in digital assets. WT trades at a forward P/E of 17.30.

Original reporting
insidermonkey.com
Published Sep 25, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 12:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Should You Buy WisdomTree (WT) Stock After Its Latest Crypto Move? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$WTBullishMed
01

Why it matters

The MoonPay integration could unlock new retail inflows and enhance tokenized product visibility, potentially re‑rating the stock.

02

Market read

A fresh strategic partnership that may drive future growth for a mid‑cap asset manager.

03

What to watch

Debt repurchase losses and high effective tax rate could limit near‑term profitability.

Relevance 7/10Novelty 7/10Timing: post-announcement on Sep 17

Background

WisdomTree is a traditional ETF sponsor transitioning to blockchain‑native services, reporting strong operating metrics but recent GAAP losses from debt retirements.

Company-level read

Ticker impact

$WTBullishHigh confidence
Context

WisdomTree announced a new partnership with MoonPay to embed its tokenized money market fund, giving access to 35M accounts.

Expected impact

upside potential if tokenized fund inflows accelerate

Evidence & confidence

First disclosure of a strategic crypto partnership; market may price in growth upside.

Market effects

Sector

Highlights growing interest in tokenized assets within the asset‑management sector.

Regional

U.S. asset managers may see increased competition from crypto‑focused distributors.

Global

Partnership could influence global tokenization trends and stablecoin adoption.

Counterpoint

What could challenge this read

The partnership may distract from core AUM growth and add regulatory risk.

Key entities

  • company
    WisdomTree

    US‑listed asset manager (WT) expanding into crypto tokenization.

  • company
    MoonPay

    Crypto infrastructure provider partnering with WisdomTree.

Read at source← All news

Related articles

JUL 31
$WTMed

WisdomTree Announces Second Quarter 2026 Results

WisdomTree, Inc. (WT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 WisdomTree Announces Second Quarter 2026 Results Record AUM of $162.9 Billion Diluted Earnings Per Share of $0.28; Adjusted Earnings Per Share of $0.31 13% Annualized Organic Flow Growth Rate Operating Margin Expanded by 780 bps Year over Year; or 900 bps, on an Adju

SEC EDGAR 8-K6 min
JUL 31
$WTMed

WisdomTree (NYSE:WT) Delivers Strong Q2 CY2026 Numbers

Asset management firm WisdomTree (NYSE: WT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 57.3% year on year to $177.2 million. Its non-GAAP profit of $0.31 per share was 17.3% above analysts’ consensus estimates. Is now the time to buy WisdomTree? Find out by accessing our full research report, it’s free. "The second quarter demonstrated the quality of WisdomTree's growth.

financialcontent.com3 min
JUN 5
$WTMedAI 8/10

WisdomTree (WT) Launches Physical AI, Humanoids, Drones ETF (WDRN) Focused on Real-World Automation

WisdomTree (NYSE:WT) launched the Physical AI, Humanoids, and Drones ETF (WDRN) on May 14, targeting companies applying AI to physical tasks. The fund has a 0.45% expense ratio and focuses on humanoid robotics, autonomous drones, smart manufacturing, and logistics automation, using a rules-based, quarterly rebalanced index. The report says it aims to track the shift from digital AI to real-world automation.

finance.yahoo.com4 min
OCT 1
$LLYMedAI 8/10

Eli Lilly And Company Announces Post-Hoc Analyses Of ATTAIN-1 Showing Foundayo Is Associated With Significant Reductions In Predicted 10-Year Risk Of Type 2 Diabetes And Cardiovascular Disease

Eli Lilly announced post-hoc analyses of ATTAIN-1 showing Foundayo reduced predicted 10-year risk of type 2 diabetes and cardiovascular disease. At 72 weeks, reductions were 45.0%, 50.0%, and 57.0% for diabetes and 18.0% for cardiovascular disease at different doses. Foundayo is FDA-approved for weight management.

marketscreener.com2 min